微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2022, Vol. 14 ›› Issue (3): 294-300.doi: 10.3969/j.issn.1674-5671.2022.03.08

• 临床研究 • 上一篇    下一篇

LINC01215在结直肠癌组织中的表达及其临床意义

  

  1. 广州医科大学公共卫生学院；广州医科大学附属第二医院胃肠外科；广州医科大学附属第六医院消化内科  
  • 出版日期:2022-06-25 发布日期:2022-06-30
  • 通讯作者: 彭铁立 E-mail： pengtl@163.com
  • 基金资助:
     国家自然科学基金面上项目(81973111)；2020年度广医附六院开放课题基金项目(202011-104)

 Expression of LINC01215 in colorectal cancer tissues and its clinical significance

  • Online:2022-06-25 Published:2022-06-30

PDF (PC)

245

赞

摘要：  目的 探讨LINC01215在结直肠癌（colorectal cancer，CRC）组织中的表达及其临床意义。方法 利用TCGA数据库分析LINC01215在CRC组织及其癌旁正常组织中的表达，并分析其与预后的关系；采用RT-qPCR检测2009年3月至2012年1月在广州医科大学附属第二医院诊治的137例CRC患者癌组织及其癌旁正常组织中LINC01215的表达水平，并分析其与患者临床病理特征的关系。通过MEM网站获取LINC01215靶基因并进行GO注释和KEGG分析。基于富集结果，对LINC01215进行单样本基因集富集分析（ssGSEA)和药物敏感性分析。结果 TCGA数据库分析结果显示，LINC01215在CRC组织中的表达水平低于癌旁正常组织（P<0.001）。临床标本验证结果显示，LINC01215在CRC组织中的表达水平低于癌旁正常组织（P=0.001），且与组织分化程度相关（P=0.037)。TCGA数据库分析结果显示，LINC01215高表达组的中位总生存时间明显高于LINC01215低表达组［96个月（95%CI：80~113个月) vs 82个月（95%CI：70~95个月)，P=0.002］。LINC01215低表达是CRC预后不良的危险因素（HR=1.69，95%CI：1.13~2.51，P=0.010)。GO和KEGG富集分析显示，LINC01215相关的靶基因主要参与蛋白质结合、T细胞受体等信号通路，ssGSEA显示LINC01215与28种免疫细胞相关（均P<0.05）。 药物敏感性分析显示LINC01215与Chelerythrine、Sapacitabine、Fenretinide、Hydroxyurea等药物敏感性有关（均P<0.05）。结论 LINC01215在CRC中低表达且与预后不良相关，其可能通过参与调节T细胞受体等信号通路影响CRC发生发展过程。

关键词: 结直肠癌, 长链非编码RNA, LINC01215, 生物信息学, 免疫浸润

Abstract:  Objective To investigate the expression of LINC01215 in colorectal cancer (CRC) tissues and its clinical significance. Methods The expression of LINC01215 in CRC tissues and adjacent normal tissues, and its relationship with prognosis were analyzed by TCGA database. The expression levels of LINC01215 in cancer tissue and adjacent normal tissue samples of 137 CRC patients diagnosed and treated in the Second Affiliated Hospital of Guangzhou Medical University from March 2009 to January 2012 were detected by RT-qPCR and the relationship between these expressions and clinicopathological characteristics was analyzed. The LINC01215 target genes were obtained from the MEM website and GO annotation and KEGG analysis were performed. According to the result of functional analysis, single-sample gene set enrichment analysis (ssGSEA) and drug sensitivity analysis were performed on LINC01215. Results TCGA database analysis showed that the expression of LINC01215 in CRC tissues was lower than that of adjacent normal tissues (P<0.001). Clinical specimens verification revealed that the expression of LINC01215 in CRC tissues was lower than that of adjacent normal tissues (P=0.001), and correlated with the degree of tissue differentiation (P=0.037). TCGA database analysis showed that the median overall survival of the high LINC01215 expression group was significantly higher than that of the low LINC01215 expression group ［96 months (95%CI: 80-113 months) vs 82 months (95%CI: 70-95 months), P=0.002］. Low LINC01215 expression was a risk factor for poor prognosis of CRC (HR=1.69, 95%CI: 1.13-2.51, P=0.010). GO and KEGG analysis showed that the target genes related to LINC01215 was mainly involved in protein binding, T cell receptor signaling pathway and other pathways. ssGSEA analysis found that LINC01215 was associated with 28 immune cells (all P<0.05). Drug sensitivity analysis showed that LINC01215 was related to the drug sensitivity of Chelerythrine, Sapacitabine, Hydroxyurea and Fenretinide (all P<0.05). Conclusions LINC01215 is lowly expressed in CRC and associated with poor prognosis. It may affect the occurrence and development of CRC by participating in the regulation of  T cell receptor signaling pathway and other pathways.

Key words:  Colorectal cancer, Long non-coding RNA, LINC01215, Bioinformatics, Immune infiltration

中图分类号: 

  • R735.3